Olema Pharmaceuticals, Inc.
OLMA
Price:
$12.09
Market Cap:
$692.35M
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2020-11-19
Stock Exchange
NASDAQ
Ticker
OLMA
The ROE as of September 2024 (TTM) for Olema Pharmaceuticals, Inc. (OLMA) is -44.18%
According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.18%. This represents a change of 294.13% compared to the average of -11.21% of the last 4 quarters.
Olema Pharmaceuticals, Inc. (OLMA) Historical ROE (quarterly & annually)
How has OLMA ROE performed in the past?
The mean historical ROE of Olema Pharmaceuticals, Inc. over the last ten years is -7.65%. The current -44.18% ROE has changed 477.46% with respect to the historical average. Over the past ten years (40 quarters), OLMA's ROE was at its highest in in the March 2020 quarter at 135.87%. The ROE was at its lowest in in the March 2023 quarter at -15.41%.
Average
-7.65%
Median
-15.82%
Minimum
-51.93%
Maximum
40.74%
Olema Pharmaceuticals, Inc. (OLMA) ROE by Quarter and Year
Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 270.03%
Maximum Annual ROE = 40.74%
Minimum Annual Increase = -116.52%
Minimum Annual ROE = -51.93%
| Year | ROE | Change |
|---|---|---|
| 2023 | -38.07% | -26.69% |
| 2022 | -51.93% | 108.47% |
| 2021 | -24.91% | 270.03% |
| 2020 | -6.73% | -116.52% |
| 2019 | 40.74% | 16.42% |
Olema Pharmaceuticals, Inc. (OLMA) Average ROE
How has OLMA ROE performed in the past?
The current ROE of Olema Pharmaceuticals, Inc. (OLMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-38.30%
5-year avg
-16.18%
10-year avg
-7.65%
Olema Pharmaceuticals, Inc. (OLMA) ROE vs. Peers
How is OLMA’s ROE compared to its peers?
Olema Pharmaceuticals, Inc.’s ROE is greater than Sana Biotechnology, Inc. (-71.60%), greater than Cullinan Oncology, Inc. (-28.37%), greater than aTyr Pharma, Inc. (-56.83%), greater than Zentalis Pharmaceuticals, Inc. (-44.23%), greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%), greater than Disc Medicine, Inc. (-23.78%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Orchestra BioMed Holdings, Inc. (-89.28%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Centessa Pharmaceuticals plc (-63.22%),
| Company | ROE | Market cap |
|---|---|---|
| -71.60% | $979.96M | |
| -28.37% | $981.54M | |
| -56.83% | $131.12M | |
| -44.23% | $271.63M | |
| -33.08% | $172.94M | |
| -42.61% | $575.83M | |
| -54.72% | $31.04M | |
| -36.89% | $1.13B | |
| -62.74% | $295.59M | |
| -37.20% | $989.87M | |
| -24.51% | $181.50M | |
| -70.40% | $349.52M | |
| -18.48% | $317.64M | |
| -131.94% | $783.95M | |
| -23.78% | $1.43B | |
| -37.84% | $425.91M | |
| -52.10% | $142.57M | |
| -89.28% | $191.01M | |
| -152.26% | $118.44M | |
| -63.22% | $1.84B |
Build a custom stock screener for Olema Pharmaceuticals, Inc. (OLMA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Olema Pharmaceuticals, Inc. (OLMA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Olema Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Olema Pharmaceuticals, Inc. (OLMA)?
What is the highest ROE for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 3-year average ROE for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 5-year average ROE for Olema Pharmaceuticals, Inc. (OLMA)?
How does the current ROE for Olema Pharmaceuticals, Inc. (OLMA) compare to its historical average?